Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03706040 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis
A Phase 2 study of Dermatitis, sponsored by AbbVie.
- Completed
- Registry status
- Phase 2
- Development phase
- 172
- Enrollment target
- 20
- Study locations
NCT03706040: Completed Phase 2 study of Dermatitis, sponsored by AbbVie.
NCT03706040 is a Phase 2 study of Dermatitis that has completed, run by AbbVie. The registered enrollment target is 172 participants, above the 151-participant average among 6 other Dermatitis trials with a reported enrollment target (14% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03706040, a Phase 2 study of Dermatitis, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 172 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the safety and efficacy of risankizumab for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents.
Primary Outcome
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scrat
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Risankizumab
Study Locations (20)
California
- Cosmetic Dermatology of Orange County /ID# 205801 - Anaheim
- Center for Dermatology Clinical Research /ID# 204950 - Fremont
- Integrative Skin Science and Research /ID# 212486 - Sacramento
- Cosmetic Laser Dermatology /ID# 210560 - San Diego
- Therapeutics Clinical Research /ID# 203422 - San Diego
Michigan
- Oakland Hills Dermatology /ID# 217453 - Auburn Hills
- Duplicate_Great Lakes Research, Inc. /ID# 206447 - Bay City
- Grekin Skin Institute /ID# 210485 - Warren
Georgia
- MetroDerm ACC Research /ID# 205958 - Atlanta
- Skin Care Physicians of Georgia /ID# 213188 - Macon
Alabama
- UAB Department of Dermatology /ID# 211561 - Birmingham
Arizona
- Cognitive Clinical Trials /ID# 208895 - Scottsdale
Colorado
- Colorado Center for Dermatology, PLLC /ID# 216260 - Centennial
Florida
- Park Avenue Dermatology, PA /ID# 203378 - Orange Park
Illinois
- University Dermatology and Vein Clinic, LLC /ID# 210702 - Darien
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2018-12-27 |
| Est. Completion | 2021-04-26 |
| Phase | Phase 2 |
What the finished NCT03706040 record still lists
NCT03706040 is an interventional study that assigns participants to a tested intervention. The registered 172 participants enrollment target is mid-sized for trials with a published cap, above the 151-participant average among 6 other Dermatitis trials with a reported enrollment target (14% higher).
The record links to 1 condition, with Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03706040 names 20 study sites across 13 states, led by California, Michigan, Georgia.
Frequently Asked Questions
What is clinical trial NCT03706040 about?
NCT03706040 is a clinical study titled "A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis". The purpose of this study is to assess the safety and efficacy of risankizumab for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents.
What is the current status of trial NCT03706040?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 172 participants. The study started on 2018-12-27. Estimated completion is 2021-04-26.
What conditions does trial NCT03706040 study?
This clinical trial studies the following conditions: Dermatitis.
What interventions are being tested in trial NCT03706040?
The interventions under investigation include: Placebo (BIOLOGICAL), Risankizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03706040?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03706040 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effects of Treatments on Atopic Dermatitis
RECRUITING · Phase 2
-
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Infant Fecal Insult Study
COMPLETED · NA
-
Evaluating for Contact Allergies in Patients With Chronic Urticaria
COMPLETED
-
Assessment of Digital Imaging as a Tool for Diagnosing Psoriasis, Hand Rashes and Unusual Moles
COMPLETED
-
Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04801797 · 172 participants · Phase 2
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
- NCT04867317 · 172 participants · Phase 3
Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)
- NCT05357040 · 172 participants · Phase 2
Antidepressant Effects of Nitrous Oxide
- NCT05587517 · 172 participants · Phase 2
A Clinical Trial of Interventions to Support Family Surrogates of Critically Ill Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI